In the above article [Liu H-J, Zhang C-Y, Song F, Xiao T, Meng J, Zhang Q, Liang C-L, Li S, Wang J, Zhang B, Liu Y-R, Sun T, and Zhou H-G (2015) J Pharmacol Exp Ther 353: 573-581 DOI: https://doi.org/10.1124/jpet.115.223107], the authors discovered a couple of mistakes were accidentally introduced during the preparation of Figs. 7 and 8. These errors do not change the results and conclusions of the paper.
In Fig. 7B, there was an error in the experimental group annotation. The Normal control should be diabetic control, and the diabetic control should be pioglitazone-30. Revised Fig. 7 is provided below:
In Fig. 8A, we found that A3 and A4 are all from the pioglitazone group. So we deleted one of the pictures of pioglitazone and added the picture of MDCCCL1636 group. And the revised figure was as below:
The HTML and PDF versions of the article have been corrected.
The authors regret this error and apologize for any inconvenience this may have caused.
- Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics
In this issue
Correction to “A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor ɣ with Excellent Effect on Insulin Resistance and Type 2 Diabetes”
